DK3555132T3 - Antistoffer mod lif og anvendelser deraf - Google Patents

Antistoffer mod lif og anvendelser deraf Download PDF

Info

Publication number
DK3555132T3
DK3555132T3 DK17840489.3T DK17840489T DK3555132T3 DK 3555132 T3 DK3555132 T3 DK 3555132T3 DK 17840489 T DK17840489 T DK 17840489T DK 3555132 T3 DK3555132 T3 DK 3555132T3
Authority
DK
Denmark
Prior art keywords
lif
antibodies
Prior art date
Application number
DK17840489.3T
Other languages
English (en)
Inventor
Johan Fransson
Jean-Philippe Julien
Swetha Raman
Suarez Joan Seoane
Folgueira Judit Anido
Original Assignee
Medimmune Ltd
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Fundacio Privada Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Medimmune Ltd
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Application granted granted Critical
Publication of DK3555132T3 publication Critical patent/DK3555132T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17840489.3T 2016-12-19 2017-12-18 Antistoffer mod lif og anvendelser deraf DK3555132T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (1)

Publication Number Publication Date
DK3555132T3 true DK3555132T3 (da) 2024-02-05

Family

ID=67138942

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17840489.3T DK3555132T3 (da) 2016-12-19 2017-12-18 Antistoffer mod lif og anvendelser deraf

Country Status (21)

Country Link
US (2) US11390670B2 (da)
EP (2) EP3555132B1 (da)
JP (3) JP7100056B2 (da)
KR (2) KR20230125099A (da)
CN (2) CN118652335A (da)
AU (1) AU2017381585A1 (da)
BR (1) BR112019012691A2 (da)
CA (1) CA3047528A1 (da)
CL (2) CL2019001717A1 (da)
DK (1) DK3555132T3 (da)
ES (1) ES2971126T3 (da)
FI (1) FI3555132T3 (da)
HR (1) HRP20240195T8 (da)
HU (1) HUE065241T2 (da)
IL (2) IL267450B (da)
LT (1) LT3555132T (da)
MX (2) MX2019007376A (da)
PL (1) PL3555132T3 (da)
RS (1) RS65187B1 (da)
SA (1) SA519402119B1 (da)
SI (1) SI3555132T1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
JP2023504642A (ja) * 2019-12-04 2023-02-06 メドイミューン・リミテッド Ｌｉｆに対する抗体及びその使用
CA3203886A1 (en) 2020-12-31 2022-07-07 Yanni CONG Human lifr antigen binding protein, preparation method therefor, and application thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
AU4241693A (en) 1992-05-15 1993-12-13 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
MX9707939A (es) 1995-04-24 1997-12-31 Genentech Inc Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
EA201100642A1 (ru) 2005-04-25 2011-12-30 Пфайзер Инк. Антитела к миостатину
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20110135645A1 (en) 2006-10-04 2011-06-09 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
KR102420934B1 (ko) 2013-03-11 2022-07-15 젠자임 코포레이션 과글리코실화된 결합 폴리펩티드
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
JP6488520B2 (ja) 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
WO2015040243A2 (en) 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
DK3055327T3 (da) 2013-10-09 2019-03-11 Res Found Dev Monoklonale OLFML-3-antistoffer og anvendelser deraf
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
CN106103480B (zh) 2014-01-10 2021-10-22 安奈普泰斯生物有限公司 针对白介素-33(il-33)的抗体
PT3129067T (pt) 2014-03-19 2023-03-22 Genzyme Corp Glicomanipulação em sítios específicos de frações de direcionamento
CN106687134A (zh) 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법

Also Published As

Publication number Publication date
US20190352389A1 (en) 2019-11-21
CN111868086A (zh) 2020-10-30
JP2024075682A (ja) 2024-06-04
US20230042095A1 (en) 2023-02-09
JP2020512388A (ja) 2020-04-23
US11390670B2 (en) 2022-07-19
JP2022130632A (ja) 2022-09-06
HUE065241T2 (hu) 2024-05-28
IL294088B1 (en) 2023-06-01
RS65187B1 (sr) 2024-03-29
HRP20240195T1 (hr) 2024-04-26
BR112019012691A2 (pt) 2019-11-19
IL294088B2 (en) 2023-10-01
LT3555132T (lt) 2024-02-26
EP3555132A1 (en) 2019-10-23
JP7100056B2 (ja) 2022-07-12
CN118652335A (zh) 2024-09-17
SA519402119B1 (ar) 2023-02-19
MX2024003178A (es) 2024-03-25
HRP20240195T8 (hr) 2024-05-24
KR102599557B1 (ko) 2023-11-07
IL267450B (en) 2022-07-01
CL2019001717A1 (es) 2020-02-28
PL3555132T3 (pl) 2024-04-22
CL2021000950A1 (es) 2021-11-26
IL294088A (en) 2022-08-01
CA3047528A1 (en) 2018-06-28
EP4321219A3 (en) 2024-05-15
KR20190122652A (ko) 2019-10-30
CN111868086B (zh) 2024-07-16
EP4321219A2 (en) 2024-02-14
MX2019007376A (es) 2020-02-07
FI3555132T3 (fi) 2024-02-08
SI3555132T1 (sl) 2024-04-30
EP3555132B1 (en) 2023-11-15
AU2017381585A1 (en) 2019-07-18
ES2971126T3 (es) 2024-06-03
IL267450A (en) 2019-08-29
KR20230125099A (ko) 2023-08-28
JP7459173B2 (ja) 2024-04-01

Similar Documents

Publication Publication Date Title
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
DK3303396T3 (da) Antistoffer mod ox40 og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3354661T3 (da) Fuldstændigt humant antistof mod human CD137 og anvendelse deraf
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3551664T3 (da) Antistoffer og polypeptider rettet mod cd127
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf